Filippo Cademartiri on Why Vascular Health Is Cognitive Health
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn:
”’When the Heart and Brain Fail Together: Why Vascular Health Is Cognitive Health’
Cognitive impairment and cardiovascular disease are deeply connected in both biology and care delivery.
New evidence highlights that cognitive decline isn’t just an outcome of aging — it affects how patients receive and respond to heart care, and conversely, vascular health shapes cognitive trajectories.
People with cardiovascular disease (CVD) are at higher risk for cognitive impairment due to shared mechanisms like hypertension, cerebral hypoperfusion, inflammation, atrial arrhythmias, and microvascular injury.
Importantly, cognitive impairment reduces engagement with care: lower treatment adherence, delayed help-seeking, and under-prescription of guideline-directed therapies are all more common.
This creates a vicious cycle where heart disease worsens cognition and impaired cognition undermines cardiovascular care.
Therapeutically, progress in vascular cognitive impairment and dementia (VCID) has been modest compared to Alzheimer’s, but meaningful strategies exist.
Symptomatic cognitive enhancers (e.g., donepezil, memantine) may offer modest benefits, especially in mixed pathology.
Behavioral and environmental interventions remain first-line for neuropsychiatric symptoms.
The greatest impact comes from vascular risk management: aggressive control of blood pressure, diabetes, atrial fibrillation, smoking cessation, and promotion of physical activity not only protects the heart but also slows cognitive decline.
Take-home:
Screen for cognitive impairment in all cardiac patients
Treat the whole patient: cardiovascular + cognitive risk
Focus on aggressive vascular prevention as dementia prevention
Tailor care plans to support adherence and decision-making
Better cardiovascular health equals better brain health.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI
-
Sep 5, 2026, 11:39Julie Rayes: Sepsis Rewrites the Role of Mast Cells in Thrombosis
-
Sep 5, 2026, 11:30Shirley D’Sa: Chemoimmunotherapy in Cold Agglutinin Disease and WM-Associated CAS
-
Sep 5, 2026, 11:29Dilini Christina Ranasinghe: An Exception to the ‘Universal Donor’ – Bombay (Oh)
-
Sep 5, 2026, 11:10Amanda Stahl: Integrating Psychosocial Care Into Comprehensive Hemophilia Treatment
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera